The molecular processes involved in the development of Parkinson’s disease are not currently known. Emerging…
Read MoreA link between physical activity and reduced Alzheimer’s and dementia biomarkers is well established, as…
Read MoreAlterity Therapeutics released topline results from its Phase 2 trial of ATH434-201 in patients with…
Read MoreAlthough Parkinson’s disease primarily presents with motor symptoms, other non-motor symptoms, such as depression, anxiety,…
Read MoreIn a clinical proceedings white paper published by the Clinical Neurological Society of America (CNSA)…
Read MoreCognition Therapeutics, Inc. has announced positive results from a Phase 2 trial of CT1812 (zervimesine)…
Read MoreBioVie Inc., a clinical-stage company based in Carson City, Nevada, announced it has fully funded…
Read MoreThe National Institute of Neurological Disorders and Stroke (NINDS) describes multiple system atrophy (MSA) as…
Read MoreA recently published case study describes a 45-year-old male patient with a diagnosis of generalized…
Read MoreDrug-induced parkinsonism (DIP) is a common etiology of Parkinson’s-like motor dysfunction. DIP was discovered in…
Read More
